Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Scarring of the lung, termed pulmonary fibrosis (PF), is a chronic, progressive, and usually fatal disorder. While two anti-fibrotic drugs have recently been approved for treating PF of unknown cause (idiopathic pulmonary fibrosis or IPF), neither drug is curative, and nearly 40% of patients stop taking the prescribed drug within a year because of side effects. The study includes the use of saracatinib, an investigational drug originally developed to treat certain types of cancers, in the treatment of IPF in a Phase 1b/2a clinical trial.

The objectives of this study are to: i) evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics, and to explore the efficacy of saracatinib in IPF; ii) identify biomarkers of Src kinase activity and fibrogenesis linked to pulmonary fibrosis; and iii) explore the application of these biomarkers to assess the anti-fibrotic effect of saracatinib in IPF patients

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Jewish Health
• Collaborators: AstraZeneca; Icahn School of Medicine at Mount Sinai; National Center for Advancing Translational Science (NCATS); Yale University

Criteria

Inclusion Criteria:

1. IPF of any duration, confirmed or diagnosed by ILD center or expert according to Fleischner Guidelines (33)

2. Women or men >40 years of age at the time of screening

3. FVC%>45% of predicted value (GLI-2012)

4. Single breath DLCO% 30 - 79 inclusive of predicted (without bronchodilator and uncorrected for hemoglobin)

5. FEV1/FVC>70 (GLI-2012)

6. Provision of signed/dated written informed consent prior to any study-specific procedures

7. Females must be of nonchildbearing potential (defined as surgically sterilized [ie, bilateral tubal ligation, bilateral oophorectomy or complete hysterectomy] or postmenopausal [defined as 12 months with no menses without an alternative medical cause] with a follicle-stimulating hormone [FSH] > 25.8 IU/L) or use a highly effective method of contraception (defined as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; progestogen only hormonal contraception associated with inhibition of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system (IUS) for the duration of the study (from the time they sign consent) and for 3 months after the last dose of drug/matching placebo

8. Male subjects must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) for the duration of the study (fr om the time they sign consent) and for 3 months after the last dose of drug/matching placebo to prevent pregnancy in a partner. Male subjects must not donate or bank sperm for the duration of the study (from the time they sign consent) and for 3 months after the last dose of drug/matching placebo.

Exclusion Criteria:

1. Requirement for supplemental oxygen > 4 L/min at rest to maintain saturation > 90%

2. Active infection at screening or randomization

3. Known active or latent hepatitis B or C

4. Life expectancy for disease other than IPF < 2.5 years (Investigator assessment)

5. Listed for lung transplantation

6. Taking pirfenidone or nintedanib in the last 4 weeks

7. Pregnancy or lactation

8. Known allergic reactions to components of saracatinib

9. Treatment with another investigational drug or other intervention within 8 weeks

10. Current smoker or tobacco use within 4 months

11. Major surgery within the past 2 months

12. Advanced hematologic, renal, hepatic, any lung disease determined by the investigator to be non-IPF related or metabolic disease that, in the opinion of the investigator, would make it unsafe for the person to receive study drug.

13. Previous lung transplantation

14. Inability to attend scheduled study visits

15. Inability to give informed consent

16. Inability to perform pulmonary function testing

17. History of malignancy in the past two years, other than squamous or basal cell skin cancer

18. Previous acute exacerbation of IPF requiring hospitalization and/or antibiotics within 90 days before the first dose of the investigational product

19. Liver function test results ≥3× upper limit of normal (ULN) liver isoform of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), or alkaline phosphatase (ALP) or ≥2×ULN total bilirubin (excepting documentation of benign hereditary cause). An isolated total bilibrubin elevation (ie, no significant concomitant elevation in ALT or AST) at baseline of ≤ 2xULN is permitted. If there is concomitant elevation in ALT or AST to ≤3xULN, then the threshold for total bilirubrin is ≤1.5xULN.

20. Creatinine clearance <30 mL/min calculated by Cockcroft-Gault formula

21. Known pulmonary hypertension (PH) requiring PH-specific treatment

22. Chronic oral corticosteroids at doses greater than prednisone 10 mg/day (or equivalent)

23. Refer to 6.5 Concomitant Therapy for exclusions based on co-medications